{"entity":{"id":"nct07349069","kind":"trial","name":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","aka":[],"tldr":"A phase 3 trial testing HRS-8080 in HR-positive / HER2-negative breast cancer, now recruiting.","summary":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer is a phase 3 interventional study registered as NCT07349069, led by Shandong Suncadia Medicine, and recruiting on the registry. Official title: A Randomised, Open-Label, Phase III Trial to Compare HRS-8080 Versus Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer Who Have Received at Least 2 Years of Standard Adjuvant Endocrine Therapy. Planned enrolment is 5500 participants (estimated). The study started in 2026-03-04 and primary completion is expected in 2030-12. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07349069","url":"https://clinicaltrials.gov/study/NCT07349069"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","hr-positive-early-high-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["hrs-8080"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07349069","phase":"3","setting":"A Randomized, Open-Label, Phase III Trial to Compare HRS-8080 Versus Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer Who Have Received at Least 2 Years of Standard Adjuvant Endocrine Therapy","sponsor":"Shandong Suncadia Medicine","started":"2026-03-04","startedType":"actual","enrolled":5500,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07349069/","neighbours":{"cancer":[{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"hrs-8080","kind":"drug","name":"HRS-8080","route":"/drugs/hrs-8080/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}